Botanix Pharmaceuticals Limited (BOT) Price & Analysis

Compare

138 Followers

BOT Stock Chart & Stats

AU$0.15

>-AU$0.01(-1.09%)

At close: Jan 09 4:00 PM EST

AU$0.15

>-AU$0.01(-1.09%)

Day’s Range― - ―

52-Week RangeAU$0.11 - AU$0.54

Previous CloseN/A

Volume8.15M

Average Volume (3M)8.47M

Market Cap

AU$285.75M

Enterprise ValueAU$562.64M

Total Cash (Recent Filing)AU$64.97M

Total Debt (Recent Filing)AU$1.22M

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Mar 04, 2026

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding1,970,660,000

10 Day Avg. Volume7,344,780

30 Day Avg. Volume8,473,310

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)7.26

Price to Sales (P/S)101.98

P/FCF Ratio-7.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$1.14

Price Target Upside660.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe market for treatments is ~$1.6 billion annually and projected to grow to $2.8 billion by 2030.

Prescription GrowthTotal prescriptions for Sofdra have grown month over month and experienced 323.5% growth in 4Q versus 3Q, driven by new patient acquisition and refill compliance.

Revenue GrowthSofdra net revenue increased from $0.7 million in 3Q to $4.3 million.

Bears Say

Royalty AgreementBotanix will receive 50% of the royalties Kaken receives from Dongwha on the latter’s net sales of Sofpironium Bromide in South Korea.

Sales Force ExpansionThe company has expanded its sales force from 27 to 33, with a total of 17 additional sales professionals expected to be fully trained and certified.

Botanix Pharmaceuticals Limited News

Botanix Pharmaceuticals Opts Out of ASX Waiver for Loan Facility

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an update. Botanix Pharmaceuticals announced that it has received a...

3d ago

BOT

Botanix Pharmaceuticals to Present at Canaccord Conference in Noosa

An update from Botanix Pharmaceuticals Limited ( ($AU:BOT) ) is now available. Botanix Pharmaceuticals announced that its CEO,...

4d ago

BOT

Strong U.S. Launch and Market Potential Propel Botanix Pharmaceuticals to ‘Buy’ Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Botanix Pharmaceuticals Limited. The associated price...

4d ago

Botanix Pharmaceuticals Releases Q1 FY26 Investor Update

The latest update is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals Limited has released its...

5d ago

BOT

Botanix Pharmaceuticals Schedules Annual General Meeting for November 2025

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has shared an announcement. Botanix Pharmaceuticals Limited has announced its Annual General...

8d ago

BOT

Botanix Pharmaceuticals Schedules Annual General Meeting for November 2025

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has provided an announcement. Botanix Pharmaceuticals Limited has announced its Annual General...

8d ago

BOT

Botanix Pharmaceuticals Announces Cessation of Securities

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) just unveiled an announcement. Botanix Pharmaceuticals Limited has announced the cessation of...

8d ago

BOT

Botanix Pharmaceuticals Issues New Securities to Boost Employee Engagement

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has shared an announcement. Botanix Pharmaceuticals Limited announced the issuance of 4.5...

8d ago

BOT

Botanix Pharmaceuticals Announces Director’s Securities Transfer

The latest update is out from Botanix Pharmaceuticals Limited ( ($AU:BOT) ). Botanix Pharmaceuticals Limited has announced a...

16d ago

BOT

Botanix Pharmaceuticals Expands Market Presence with New Securities Quotation

Botanix Pharmaceuticals Limited ( ($AU:BOT) ) has issued an update. Botanix Pharmaceuticals Limited announced the quotation of 9,333,334...

17d ago

BOT

BOT FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?

Botanix Pharmaceuticals Limited lowest share price was AU$0.10 and its highest was AU$0.54 in the past 12 months.

What is Botanix Pharmaceuticals Limited’s market cap?

Botanix Pharmaceuticals Limited’s market cap is AU$285.75M.

When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?

Botanix Pharmaceuticals Limited’s upcoming earnings report date is Mar 04, 2026 which is in 131 days.

How were Botanix Pharmaceuticals Limited’s earnings last quarter?

Botanix Pharmaceuticals Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.02.

Is Botanix Pharmaceuticals Limited overvalued?

According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Botanix Pharmaceuticals Limited pay dividends?

Botanix Pharmaceuticals Limited does not currently pay dividends.

What is Botanix Pharmaceuticals Limited’s EPS estimate?

Botanix Pharmaceuticals Limited’s EPS estimate is -0.02.

How many shares outstanding does Botanix Pharmaceuticals Limited have?

Botanix Pharmaceuticals Limited has 1,970,660,000 shares outstanding.

What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?

Botanix Pharmaceuticals Limited reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:BOT

Botanix Pharmaceuticals Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-90.93%

Trailing 12-Months

Asset Growth

14.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited (BOT) is an innovative clinical-stage dermatology company focused on developing treatments for skin diseases using its proprietary drug delivery technology, Permetrex. The company is primarily engaged in the research, development, and commercialization of pharmaceutical products aimed at addressing unmet needs in dermatology, with a focus on conditions such as acne, rosacea, and other skin infections.

Botanix Pharmaceuticals Limited (BOT) Earnings & Revenues

Historic Earnings Reports

BOT Stock 12 Month Forecast

Average Price Target

AU$1.14

▲(660.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","2":"AU$2","3":"AU$3","-1":"-AU$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.14,0.2830769230769231,0.42615384615384616,0.5692307692307692,0.7123076923076923,0.8553846153846154,0.9984615384615384,1.1415384615384614,1.2846153846153845,1.4276923076923076,1.5707692307692307,1.7138461538461538,1.856923076923077,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.14,0.21692307692307694,0.29384615384615387,0.37076923076923074,0.44769230769230767,0.5246153846153846,0.6015384615384615,0.6784615384615384,0.7553846153846153,0.8323076923076922,0.9092307692307692,0.986153846153846,1.063076923076923,{"y":1.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.14,0.15000000000000002,0.16,0.17,0.18000000000000002,0.19,0.2,0.21000000000000002,0.22000000000000003,0.23,0.24000000000000002,0.25,0.26,{"y":0.27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.08,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.18,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >